A5083460799- Health Sciences Research and Education
- Health and Medical Research Impacts
- Meta-analysis and systematic reviews
- RNA Interference and Gene Delivery
- Academic Writing and Publishing
- scientometrics and bibliometrics research
- Advanced biosensing and bioanalysis techniques
- Conferences and Exhibitions Management
- Virus-based gene therapy research
- Biosimilars and Bioanalytical Methods
- Academic Publishing and Open Access
- Psychiatric care and mental health services
- Chemical synthesis and alkaloids
- Global Financial Crisis and Policies
- Pharmaceutical studies and practices
- Public Relations and Crisis Communication
- Cancer Research and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Vaccine Coverage and Hesitancy
- RNA Research and Splicing
- Viral Infectious Diseases and Gene Expression in Insects
- Pharmaceutical industry and healthcare
- Evolutionary Algorithms and Applications
- SARS-CoV-2 and COVID-19 Research
- Biomedical Text Mining and Ontologies
Oxford Instruments (United Kingdom)
2016
University of Oxford
2003-2006
The University of Queensland
1994
Leicester Royal Infirmary
1979
Objectives Authors may choose to work with professional medical writers when writing up their research for publication. We examined the relationship between support and quality timeliness of reporting results randomised controlled trials (RCTs). Design Cross-sectional study. Study sample Primary reports RCTs published in BioMed Central journals from 2000 16 July 2014, subdivided into those (n=110) without (n=123). Main outcome measures Proportion items that were completely reported a...
Non-viral vectors are promising vehicles for gene therapy but delivery of plasmid DNA to post-mitotic cells is challenging as nuclear entry particularly inefficient. We have developed and evaluated a hybrid mRNA/DNA system designed bypass the barrier transfection facilitate cytoplasmic expression. This system, based on co-delivery mRNA(A64) encoding T7 RNA polymerase (T7 RNAP) with T7-driven plasmid, produced between 10- 2200-fold higher expression in primary dorsal root ganglion neuronal...
Exciting developments have recently emerged in the field of RNA therapeutics, with potential applications treatment human diseases. The second International Conference on drug development was held to highlight several novel RNA-based technologies, including different approaches silence gene expression, broad range diagnostic and therapeutic for aptamers, targeting small molecules. Highlights meeting included utilisation interference genes, both cancer viral infections, systemic silencing...
AbstractRecent progress in the field of RNA therapeutics has highlighted potential using RNA-based strategies for treatment human cancer. Emerging technologies such as small interfering (siRNA) to trigger interference (RNAi) and catalytic molecules, called ribozymes, are being developed modulate expression genes either block tumourigenesis itself, inhibit tumour growth or prevent metastasis. Delivery mRNA vectors based on positive-strand viruses alpha viruses, picornaviruses flaviviruses...
An ORCID Identifier (ORCID iD) provides an author with a unique, persistent digital identifier, providing disambiguation and increasing transparency and discoverability. We analysed the uptake use of ORCID iD by six pharmaceutical companies.
AbstractExciting developments have recently emerged in the field of RNA therapeutics, with potential applications treatment human diseases. The second International Conference on drug development was held to highlight several novel RNA-based technologies, including different approaches silence gene expression, broad range diagnostic and therapeutic for aptamers, targeting small molecules. Highlights meeting included utilisation interference genes, both cancer viral infections, systemic...